N

Neurocrine Biosciences

Develops and markets neurology-focused therapies

Director – Field Sales Training

Full-TimeUpdated on 10/15/2026
$188.3k - $257k/yr+ 35% target annual bonus + Equity-based long-term incentive program
Expert
Bachelor's, Master's
San Diego, CA, USA
In Person
TrainingCorporate & Technical Training
Company Does Not Provide H1B Sponsorship

About the job

Requirements
  • A Bachelor of Science or Bachelor of Arts degree in an applicable field and 12 or more years of applicable experience, including significant experience in sales training, learning and development, commercial capability, or a similar discipline; or a master's degree in an applicable field and 10 or more years of relevant experience.
  • Progressive pharmaceutical, biotechnology, medical device, or healthcare commercial experience, with strong knowledge of field sales organizations, sales effectiveness, and commercial operating environments.
  • Extensive learning and development and sales training experience, including strategy, curriculum architecture, instructional design, facilitation, measurement, and program implementation from concept through field execution.
  • Demonstrated second-line people leadership capabilities, including coaching leaders, building impactful teams, developing talent, strengthening succession pipelines, and sustaining engagement and accountability across teams.
  • Experience leading training organizations or learning strategies across multiple products, brands, therapeutic areas, or business units, balancing common capabilities with differentiated business needs.
  • Strong experience developing and executing product launch training programs, annual Plan of Action cycle training, new hire onboarding, and ongoing capability development.
  • Knowledge and demonstrated application of adult learning principles, blended learning methodologies, learning technology, reinforcement strategies, and performance measurement.
  • Success partnering with senior Commercial leadership and cross-functional stakeholders to identify capability needs, shape strategy, and deliver solutions with broad organizational impact.
  • Experience managing budgets, vendors, resources, and complex portfolios of concurrent learning initiatives.
  • Extensive business, commercial, and functional expertise, with the ability to translate complex strategy into operational and tactical plans.
  • Ability to develop multi-year plans, anticipate emerging business and industry needs, assess risk, and adapt priorities as conditions evolve.
  • Business acumen and judgment to lead complex cross-functional decision-making, prioritize based on strategic impact, and operate effectively amid ambiguity.
  • Relationship-building, collaboration, and influencing skills to work effectively with senior leaders and diverse cross-functional stakeholders.
  • Written, verbal, presentation, facilitation, and executive communication skills to tailor messages to varied audiences and ensure clear, consistent communication across teams.
  • Motivation, innovation, analytical and operational focus, learning agility, sound judgment, and a continuous improvement mindset.
Responsibilities
  • Establish and communicate the strategic direction, priorities, and operating model for Field Sales Training across multiple products, therapeutic areas, and commercial business units; translate Commercial strategy into actionable learning and capability plans.
  • Provide second-line leadership for the Field Sales Training organization, including leadership of people leaders and high-level individual contributors; select, coach, develop, mentor, and evaluate talent to ensure strong performance and effective operation of the function.
  • Build a shared vision across Field Sales Training teams and align team priorities with broader Commercial objectives and Neurocrine strategic direction.
  • Oversee the design, development, implementation, and evaluation of field sales learning initiatives supporting new hire onboarding, ongoing and recurrent training, product launches, Plan of Action cycle meetings, disease state and product knowledge, selling skills, messaging, and other strategic capability priorities.
  • Assess current and future sales capabilities, identify performance gaps, and ensure training solutions are appropriately scaled and tailored across distinct field teams and business needs.
  • Partner with senior leaders across Sales, Marketing, Medical, Market Access, Commercial Operations, Human Resources, Compliance, Legal, and other functions to shape and execute learning strategies that support brand, portfolio, and organizational priorities.
  • Lead cross-functional decision-making on learning priorities, resources, investments, and trade-offs, using data, business insight, and long-term organizational implications to guide decisions in complex or ambiguous situations.
  • Ensure training content and programs comply with NBI Legal, Regulatory, Compliance, and Medical requirements and reflect standards for adult learning, conduct, quality, and pharmaceutical industry compliance.
  • Advance the effectiveness and efficiency of learning through instructional approaches, blended and digital learning, learning technology, field reinforcement, measurement, and external best practices.
  • Establish performance expectations and success measures for the Field Sales Training organization; monitor outcomes and use learning analytics, business metrics, stakeholder feedback, and field insights to drive continuous improvement and measurable impact.
  • Lead talent assessment, succession planning, and targeted development to strengthen leadership capability, organizational bench strength, and readiness for future business needs.
  • Oversee departmental budgets, vendors, learning management system curriculum, control documents, resource allocation, meeting-related training operations, and financial reporting and analysis.
  • Perform other duties as assigned.
Desired Qualifications
  • Demonstrated second-line leadership experience, including experience leading people leaders and high-performing teams.
  • Experience leading training teams or learning strategies supporting multiple products and business units.

About the company

N

Neurocrine Biosciences

View

Neurocrine Biosciences develops and commercializes medicines for neurological and endocrine diseases. Its work centers on discovering and developing treatments, with INGREZZA (valbenazine) approved to treat adults with tardive dyskinesia and a pipeline of other drug candidates in various clinical stages. The company earns revenue from sales of approved medicines and from milestones and royalties from collaborations with partners. By focusing on both neurological and endocrine conditions, Neurocrine targets patients and healthcare professionals seeking therapies for conditions such as tardive dyskinesia, Parkinson's disease, and endometriosis. Its main goal is to bring therapies to market through development and commercialization, supported by ongoing research across its clinical programs to address unmet medical needs in these areas.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1992

Get referred to Neurocrine Biosciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue jumped 39.5% to $959 million, beating estimates.
  • Neurocrine raised 2026 INGREZZA guidance to $2.825 billion-$2.875 billion after strong prescriptions.
  • NBIP-1968 entered Phase 1 in August 2026, giving Neurocrine obesity upside.

What critics are saying

  • INGREZZA faces Zydus generic litigation after the March 2025 ANDA challenge.
  • DOJ requested INGREZZA sales documents in August 2025, threatening fines or restrictions.
  • VYKAT XR drew safety alarms in August 2026 after reported deaths and hospitalizations.

What makes Neurocrine Biosciences unique

  • INGREZZA led Neurocrine's CNS franchise, with Q2 2026 sales of $716 million.
  • CRENESSITY delivered $184 million in Q2 2026, validating Neurocrine's endocrinology expansion.
  • Soleno acquisition added VYKAT XR, the only approved PWS hyperphagia therapy, in May 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Parental Leave

Health Insurance

Dental Insurance

Vision Insurance

Paid Holidays

Company News

Contract Pharma
Sep 29th, 2026
Neurocrine Biosciences welcomes back Eiry Roberts as Chief Medical Officer.

Neurocrine Biosciences welcomes back Eiry Roberts as Chief Medical Officer. September 29, 2026 Content Marketing Editor Why This Matters: See our coverage of other industry executive team appointments and promotions here. Neurocrine Biosciences named Eiry Roberts, MD, Chief Medical Officer, returning Roberts to a post she held from 2018 to 2025. Roberts had remained linked with Neurocrine in the intervening time as a Strategic Advisor. Resulting from this appointment, Sanjay Keswani, MD, is departing Neurocrine by mutual agreement. Chief Medical Officer's resume. During her previous tenure, Roberts led indication expansion efforts for Ingrezza (valbenazine). She also spearheaded the development program that led to U.S. FDA approval of Crenessity (crinecerfont). Before joining Neurocrine, Roberts spent 26 years at Eli Lilly and Company, most notably as Vice President, Research and Development. Roberts served on the Board of Directors of Amicus Therapeutics prior to its April 2026 acquisition by BioMarin Pharmaceutical. Currently, she serves on the Board of Directors of Bausch Health Companies. Her new appointment as CMO at Neurocrine takes effect immediately. New meets familiar at Neurocrine. "I'm honored to assume the Chief Medical Officer role again and contribute to our mission of relieving suffering," Roberts said. "Having remained closely connected to the company as a Strategic Advisor, I am excited about the opportunities ahead. I look forward to building on the teams' progress, advancing the portfolio, and ultimately delivering meaningful benefits for patients." "We're pleased to welcome Eiry back to the Chief Medical Officer role," Neurocrine President and CEO Kyle Gano, PhD, said. "Her deep knowledge of Neurocrine, our pipeline, and our clinical development programs provides strong continuity... Eiry's experience with our portfolio positions her well to lead our clinical development efforts. I look forward to working closely with her once again." Add us as a preferred source on Google. Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

PR Newswire
Sep 28th, 2026
Neurocrine Biosciences reappoints Eiry Roberts as chief medical officer

Neurocrine Biosciences has reappointed Eiry W. Roberts, M.D., as Chief Medical Officer, effective immediately. Dr Roberts previously held the CMO position from 2018 to 2025 and has since served as a strategic adviser to the company. During her earlier tenure, Dr Roberts led indication-expansion efforts for INGREZZA and the crinecerfont development programme that resulted in FDA approval of CRENESSITY. Before joining Neurocrine in 2018, she spent 26 years at Eli Lilly and Company in senior research and development roles. By mutual agreement, Sanjay Keswani, M.D., will depart the company. CEO Kyle W. Gano noted that Dr Roberts' knowledge of Neurocrine's pipeline positions her well to lead clinical development efforts as the company advances multiple late-stage programmes.

U.S. Securities and Exchange Commission
Sep 20th, 2026
8-K

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

InfoMed News
Aug 7th, 2026
Neurocrine Biosciences announces initiation of Phase 1 clinical study evaluating NBIP-'1968, a glp-1/gip/glucagon receptor triple agonist.

Neurocrine Biosciences announces initiation of Phase 1 clinical study evaluating NBIP-'1968, a glp-1/gip/glucagon receptor triple agonist. Initiation of study marks an important milestone in advancing Neurocrine's obesity portfolio and investigational metabolic disease pipeline Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 first-in-human clinical study evaluating the safety and tolerability of NBIP-'1968, an investigational GLP-1/GIP/glucagon receptor triple agonist being developed as a therapy for obesity. "Obesity is a complex chronic disease driven by multiple biological pathways, underscoring the need for additional treatment options," said Sanjay Keswani, M.D., Chief Medical Officer, Neurocrine Biosciences. "NBIP-'1968 is designed to engage three complementary metabolic mechanisms, reflecting our commitment to exploring multiple scientific approaches to obesity." The Phase 1 study initially will evaluate the safety and tolerability of single ascending doses of NBIP-'1968 in adult participants across a range of body mass index categories, including overweight and obese. Innovations in treatment by Neurocrine bioscience. NBIP-'1968 is an internally discovered, investigational long-acting triple agonist designed for once-weekly subcutaneous administration. It targets the receptors for glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon to influence metabolic pathways involved in appetite regulation, energy balance and glycemic control. NBIP-'1968 was designed with balanced glucagon receptor activity to optimize the potential metabolic benefits of glucagon receptor activation while supporting tolerability. Neurocrine is developing NBIP-'1968 as part of a broader obesity portfolio that includes NBIP-'2118, an investigational corticotropin-releasing factor type 2 receptor agonist currently in Phase 1 development. NBIP-'1968 is intended for use in a fixed-dose combination with NBIP-'2118. The company's obesity research also includes earlier-stage programs designed to explore complementary mechanisms and extended dosing intervals. "Advancing NBIP-'1968 into the clinic marks another important step in building our obesity portfolio," said Jude Onyia, Ph.D., Chief Scientific Officer, Neurocrine Biosciences. "Our strategy is to explore complementary and differentiated mechanisms that may improve weight loss, preserve lean mass and ultimately address the diverse needs of people living with obesity." About Obesity Obesity is a chronic disease characterized by excess body fat and is associated with serious health conditions, including type 2 diabetes, cardiovascular disease, obstructive sleep apnea, metabolic dysfunction-associated steatohepatitis/fatty liver disease, certain cancers and osteoarthritis. It is driven by complex biological, environmental, and genetic factors - not simply lifestyle or willpower. Obesity has reached epidemic levels worldwide, affecting a significant proportion of adults and placing a substantial burden on public health systems. Despite recent advances in treatment, there remains a need for additional therapies that support safe, effective and sustainable long-term weight management. Current therapies can have challenges with respect to gastrointestinal tolerability, dose titration, and muscle loss. More news. August 7, 2026 August 6, 2026

Yahoo Finance
Jul 31st, 2026
Neurocrine Q2 revenue jumps 40% to $959M, beating estimates by 6%

Neurocrine Biosciences reported revenue of $959 million for the quarter ended June 2026, marking a 39.5% year-on-year increase. The figure surpassed the consensus estimate of $901.54 million by 6.37%. Earnings per share came in at $2.85, up from $1.06 a year earlier and beating the consensus estimate of $2.26 by 26.11%. Product sales reached $954.3 million, exceeding analyst estimates of $881.08 million. INGREZZA sales totalled $716 million, above the $628.59 million forecast, whilst CRENESSITY generated $184 million against an estimated $170.78 million. Collaboration revenue came in at $4.7 million, below the $6.02 million estimate and down 14.6% year-on-year. Shares rose 7.8% over the past month.